copanlisib dihydrochloride

copanlisib dihydrochloride (ALIQOPA) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.

ALIQOPA is a marketed brand name for copanlisib dihydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

copanlisib dihydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.